Comparative Pharmacology
Head-to-head clinical analysis: DROXIA versus XPOVIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROXIA versus XPOVIO.
DROXIA vs XPOVIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyurea inhibits ribonucleotide reductase, depleting deoxyribonucleotides and inducing fetal hemoglobin (HbF) synthesis.
Selective inhibitor of nuclear export (SINE) that binds to and inhibits exportin 1 (XPO1), blocking the nuclear export of tumor suppressor proteins (e.g., p53, IκB) and growth regulators, leading to their nuclear accumulation and reactivation, thereby inducing apoptosis in cancer cells.
Hydroxyurea (Drosia) for sickle cell anemia: Oral, starting dose 15 mg/kg once daily; escalate by 5 mg/kg every 12 weeks to maximum 35 mg/kg/day. For essential thrombocythemia: 15-30 mg/kg once daily. For myelodysplastic syndrome: 15-30 mg/kg once daily.
XPOVIO (selinexor) is administered orally at a dose of 80 mg (four 20 mg tablets) on days 1 and 3 of each week for multiple myeloma. For diffuse large B-cell lymphoma, the recommended dose is 60 mg (three 20 mg tablets) on days 1 and 3 of each week.
None Documented
None Documented
3–4 hours in patients with normal renal function; prolonged to 8–12 hours in moderate to severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal half-life ranges from 6 to 10 hours (mean ~7.5 h) in patients with relapsed/refractory multiple myeloma; supports twice-weekly dosing with food.
Renal: approximately 50% of absorbed dose excreted unchanged in urine. Biliary/fecal: up to 20% excreted in feces as metabolites, with less than 5% as unchanged drug.
Primarily metabolized by CYP3A4 and other pathways; <1% excreted unchanged in urine; fecal excretion accounts for ~80% of total clearance, with renal elimination minimal (<2% of dose).
Category C
Category C
Antineoplastic
Antineoplastic